Filtered By:
Specialty: Hematology
Infectious Disease: COVID-19

This page shows you your search results in order of date.

Order by Relevance | Date

Total 85 results found since Jan 2013.

Investigating the prevalence of and predictive and risk factors for pulmonary embolism in patients with COVID-19 in Nemazee Teaching Hospital
CONCLUSION: Regression analysis revealed that age, blood pressure, heart attack, and albumin levels were independent predictors of PTE.PMID:37431097 | DOI:10.5045/br.2023.2023076
Source: Blood Research - July 11, 2023 Category: Hematology Authors: Mahnaz Yadollahi Hessam Hosseinalipour Muhammad Alinaqi Mehrdad Karajizadeh Mehrdad Jowkar Kazem Jamali Maryam Yadollahi Pooria Fazeli Source Type: research

Thrombotic Complications in Children with COVID-19 and MIS-C
J Thromb Haemost. 2023 May 31:S1538-7836(23)00434-8. doi: 10.1016/j.jtha.2023.05.020. Online ahead of print.ABSTRACTCoronavirus disease 2019 (COVID-19) associated coagulopathy is multifactorial and involves inflammation driven hypercoagulability, endothelial dysfunction, platelet activation and impaired fibrinolysis. Hospitalized adults with COVID-19 are at an increased risk of both venous thrombo-embolism (VTE) and ischemic stroke, resulting in adverse outcomes including mortality. While children with COVID-19 follow a less severe course, both arterial and venous thrombosis have been reported in hospitalized children with...
Source: Thrombosis and Haemostasis - June 2, 2023 Category: Hematology Authors: Riten Kumar Michael J Rivkin Leslie Raffini Source Type: research

Prevention of Venous Thromboembolism in Medical Patients with Thrombocytopenia or with Platelet Dysfunction: The Last 10 Years
Semin Thromb Hemost DOI: 10.1055/s-0043-1769013Current guideline recommendations for primary prophylaxis of venous thromboembolism (VTE) are based on randomized clinical trials that usually exclude subjects at a potentially high risk of bleeding complications. For this reason, no specific guideline is available for thromboprophylaxis in hospitalized patients with thrombocytopenia and/or platelet dysfunction. However, except in patients with absolute contraindications to anticoagulant drugs, antithrombotic prophylaxis should always be considered, for example, in hospitalized cancer patients with thrombocytopenia, especially...
Source: Seminars in Thrombosis and Hemostasis - May 18, 2023 Category: Hematology Authors: Tufano, Antonella Brenner, Benjamin Tags: Review Article Source Type: research

Risk factors for post-discharge major thromboembolism and mortality in hospitalized patients with COVID-19 with cardiovascular comorbidities
Conclusions COVID-19 inpatients with cardiovascular disease experience high rates of ATE, VTE, or ACM through 90 days post-discharge. Age > 75 years, PAD, CAS, CHF, previous VTE, and ICU admission are independent risk factors.PMID:37146648 | DOI:10.1055/a-2087-3003
Source: Thrombosis and Haemostasis - May 5, 2023 Category: Hematology Authors: Dimitrios Giannis Mark Goldin Husneara Rahman Cristina P Sison Martin Lesser Sam Ngu James Tsang Michael Qiu Shreya Sanghani Jackson Yeh Miltiadis Matsagkas Eleni Arnaoutoglou Alex C Spyropoulos Source Type: research